Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial.

ABSTRACT:

Background and purpose

Randomized trials have indicated a benefit for endovascular therapy in appropriately selected stroke patients at 3 months, but data regarding outcomes at 12 months are currently lacking.

Methods

We compared functional and quality-of-life outcomes at 12 months overall and by stroke severity in stroke patients treated with intravenous tissue-type plasminogen activator followed by endovascular treatment as compared with intravenous tissue-type plasminogen activator alone in the Interventional Management of Stroke III Trial. The key outcome measures were a modified Rankin Scale score ≤2 (functional independence) and the Euro-QoL EQ-5D, a health-related quality-of-life measure.

Results

656 subjects with moderate-to-severe stroke (National Institutes

SUBMITTER: Palesch YY 

PROVIDER: S-EPMC4414900 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature